Clinical trials: Moderate to Severe Dry Eye
Dry Eye
Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Dry Eye
The purpose of this study is to explore the efficacy and safety of CsA ophthalmic gel in the treatment of moderate to severe tear deficiency dry eye with different dosage, frequency and concentration, and to preliminarily…
- Trial name
- NCT03676335
- Testing
- CsA eye gel, CsA for eye emulsion, Hypromellose Eye Drops
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Healthy Subjects, Moderate to Severe Keratoconjunctivitis Sicca (KCS)
Three Dimension Tomography of Eye Structures by White Light Imaging Device
The purpose of this study is to investigate the ability of an imaging device, developed by AdOM Advanced Optical Technologies Ltd. ("AdOM").
- Conditions
- Healthy Subjects, Moderate to Severe Keratoconjunctivitis Sicca (KCS), Dry Eye Syndrome (DES)
- Trial name
- 3D-WLT (NCT02424266)
- Testing
- None invasive imaging of the tear film (AdOM)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Dry Eye Syndrome
To Demonstrate the Non-inferiority of Eyestil Protection® Compared to Vismed® in Terms of Clinical Performance
This is a national, prospective, multicenter, comparative, randomized, single-blinded non-inferiority study performed in two parallel groups.
- Trial name
- NCT03803722
- Testing
- Eyestil Protection® unidose
- Where
- 11 sites in France, Spain
- Volunteers
- 21 people
- Sponsor
- SIFI SpA
Dry Eye Syndromes
Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients
This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56 5%) compared to control drug(vehicle) in Patients with Dry Eye Disease.
- Trial name
- NCT06291194
- Testing
- AJU-S56 5%
- Where
- South Korea
- Volunteers
- 396 people
- Sponsor
- AJU Pharm Co., Ltd.
Dry Eye Syndromes
Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes
The purpose of this clinical Study is TJCS Eye Drops 0.05%(Cyclosporine ophthalmic nano-emulsion) group and Restasis Eye Drops 0.05%(Cyclosporine ophthalmic suspension) group 12 weeks after treatment, each treatment group…
- Trial name
- NCT02461719
- Testing
- CYPORIN N EYE DROPS 0.05%(TJCS eye drop), Restasis
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Moderate to Severe Dry Eye
A Clinical Trial to Evaluate the Clinical Efficacy of Cyclosporine 0.1% (Ikervis®) for Moderate to Severe Dry Eye Patients. (IKE-03-SWITCHING)
A clinical trial to evaluate the efficacy and safety of Cyclosporine 0.1% (Ikervis®) for moderate to severe dry eye patients who changed to Cyclosporine 0.1% eye drop(Ikervis®) due to lack of treatment effects of the previous…
- Trial name
- NCT04775303
- Testing
- Cyclosporine 0.1% (Ikervis®) eye drop
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Yonsei University
Sjogrens Syndrome
Nipocalimab in Moderate to Severe Sjogren's Disease
The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD).
- Trial name
- DAFFODIL (NCT06741969)
- Testing
- Nipocalimab, Standard of care treatment
- Where
- 254 sites in United States, Argentina and 26 more
- Volunteers
- 655 people
- Sponsor
- Janssen Research & Development, LLC
Dry Eye Syndrome
Study of TOP1630 for Dry Eye Syndrome
In subjects with Dry Eye Syndrome (DES): The primary objective of this study is to confirm the efficacy of TOP1630 0.1% Ophthalmic Solution TID OU compared to placebo treatment at Day 29 on pre-specified sign and symptom…
- Trial name
- THEIA-1 (NCT03833388)
- Testing
- TOP1630 0.1% Ophthalmic Solution TID OU
- Where
- 4 sites in United States
- Volunteers
- 202 people
- Sponsor
- Topivert Pharma Ltd
Dry Eye Syndrome
Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Comparison of the efficacy and safety of T2762 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome
- Trial name
- NCT02023268
- Testing
- T2762, Vismed®
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Laboratoires Thea
Dry Eye Disease
Comparison of Efficacy Between 100% Platelet-rich Plasma and 100% Serum Eye Drops in Dry Eye Disease
Dry eye disease (DED) is a common eye problem, affecting 5% to 50% of the world population. Although the disease is not fatal, it substantially reduces quality of life and creates a high economic burden as high as over 50 billion…
- Trial name
- NCT04683796
- Testing
- 100% Autologous platelet rich plasma, 100% Autologous serum
- Where
- Thailand
- Volunteers
- 96 people
- Sponsor
- Mahidol University
Dry Eye Disease (DED), Tear Break-Up Time
Efficacy of 0.28% Sodium Hyaluronate Eye Drops in Patient With Moderate to Severe Dry Eye
This study aimed to evaluate the efficacy and safety of 0.28% preservative-free SH and 0.18% SH eye drops in patients with dry eye disease.
- Conditions
- Dry Eye Disease (DED), Tear Break-Up Time, Tear Disorder, Tear Film Insufficiency
- Trial name
- NCT06860659
- Testing
- 0.28% Sodium Hyaluronate , preservative free eye drops, 0.18% Sodium Hyaluronate , preservative free eye drops
- Where
- Thailand
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Sjögren, Sjogren Disease
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.
- Conditions
- Sjögren, Sjogren Disease, Sjogren's Syndrome
- Trial name
- NCT07041099
- Testing
- CLN-978
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 36 people
- Sponsor
- Cullinan Therapeutics Inc.
Dry Eye, Dry Eye Disease (DED)
A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.
The purpose of this randomized, controlled, multicenter study is to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED. The primary question it aims to answer is if TTAX03 is safe.
- Conditions
- Dry Eye, Dry Eye Disease (DED), Dry Eye Disease With Severe Keratitis
- Trial name
- NCT06780306
- Testing
- TTAX03
- Where
- 9 sites in United States
- Volunteers
- 74 people
- Sponsor
- BioTissue Holdings, Inc
Dry Eye Syndromes
Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease
This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis® X) in patients with moderate to severe dry eye disease in two stages. Up to 3 doses will be studied in Stage 2 based on results from Stage 1.
- Trial name
- NCT02013791
- Testing
- Vehicle, Cyclosporine New Ophthalmic Formulation
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Allergan
Dry Eye Disease
HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)
The purpose of this study is to determine whether SYL1001 ophthalmic solution is safe and effective in the treatment of signs and symptoms of Dry Eye Disease.
- Trial name
- NCT03108664
- Testing
- SYL1001 ophthalmic solution, Vehicle opthalmic solution
- Where
- 40 sites in Estonia, Germany and 4 more
- Volunteers
- 330 people
- Sponsor
- Sylentis, S.A.
Keratoconjunctivitis Sicca
Trial of CF101 to Treat Patients With Dry Eye Disease
Eligible patients with dry eye will be treated with CF101 or placebo twice daily for 24 weeks. Disease activity will be assessed using evaluations of ocular surface integrity, tear production, and patient symptoms.
- Trial name
- NCT01235234
- Testing
- CF101
- Where
- Israel
- Volunteers
- 236 people
- Sponsor
- Can-Fite BioPharma
Moderate to Severe Dry Eye
A Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients
This study is a multi-site, unmasked PMS Study. The purpose of the study is to evaluate the physical effects of Systane Lubricant Eye Drops.
- Trial name
- NCT01311609
- Testing
- Systane
- Volunteers
- 300 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome
The main purpose of this study is to establish whether RP101 can reduce symptoms of dry eye syndrome in post-menopausal women.
- Trial name
- NCT03821415
- Testing
- RP101
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 104 people
- Sponsor
- Redwood Pharma AB
Dry Eye
Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular Dryness
This study is a multicentric, comparative, randomized, investigator-blinded, in parallel groups study to demonstrate the non-inferiority of DM05 in comparison with Optive™, in terms of cornea and conjunctiva staining (Oxford…
- Trial name
- NCT03517748
- Testing
- DM05 eye drops, Optive™ eye drops
- Volunteers
- 80 people
- Sponsor
- Horus Pharma
Dry Eye Syndrome
Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.
The objective is to demonstrate the non-inferiority of T2769 compared to Hylo-Forte® in terms of the change from baseline (D1) in total ocular surface staining score assessed on Oxford 0-15 scale, in the study eye at the D36…
- Trial name
- NCT06375499
- Testing
- T2769, Hylo-Forte®
- Where
- 4 sites in Czechia, Hungary
- Volunteers
- 74 people
- Sponsor
- Laboratoires Thea